Sökning: onr:"swepub:oai:DiVA.org:uu-492635" >
Heparin Conjugate P...
Heparin Conjugate Pretreatment of Kidneys From Deceased Donors Before Transplantation : Results From the First-in-human Randomized Phase I Trial
-
- Sedigh, Amir (författare)
- Uppsala universitet,Transplantationskirurgi
-
Lundgren, Torbjörn (författare)
-
- Lindnér, Per, 1956 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för kirurgi,Institute of Clinical Sciences, Department of Surgery
-
visa fler...
-
Nordström, Johan (författare)
-
- Magnusson, Peetra (författare)
- Uppsala universitet,Klinisk immunologi
-
- Jönsson, Janniz (författare)
- Uppsala universitet,Transplantationskirurgi,Klinisk immunologi
-
- Carlsson, Fredrik (författare)
- Uppsala universitet,Klinisk immunologi,Corline Biomedical AB, Uppsala, Sweden.
-
- Ploeg, Rutger (författare)
- Nuffield Department of Surgical Sciences, Oxford Transplant Centre, University of Oxford, Oxford, United Kingdom.
-
- Lorant, Tomas, 1975- (författare)
- Uppsala universitet,Transplantationskirurgi
-
visa färre...
-
(creator_code:org_t)
- 2022-12-22
- 2023
- Engelska.
-
Ingår i: Transplantation direct. - : Wolters Kluwer. - 2373-8731. ; 9:1
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://gup.ub.gu.se...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background. Pretreating porcine kidneys with corline heparin conjugate (CHC) during hypothermic machine perfusion (HMP) has been shown to reduce preservation injury and improve early kidney function. In this first-in-human phase I study, the safety and tolerability of transplanting CHC-pretreated kidneys was evaluated.Methods. CHC or placebo was added to the preservation solution during HMP of donated kidneys from deceased donors for at least 3 h before transplantation into adult patients. The primary safety endpoint was the number and severity of adverse events (AEs) and serious AEs (SAEs) during the first 30 d after transplantation.Results. In the first 30 d, 66 AEs were reported in 8 patients who received CHC-pretreated kidneys with 39 AEs in 8 patients who received placebo-pretreated kidneys (P = 0.1 in post hoc analysis). The most common AEs were hypertension (CHC, n = 5; placebo, n = 2) and anemia (CHC, n = 5; placebo, n = 2). Most AEs were assessed as mild (58%) or moderate (39%) and not related to treatment (95%). There were 2 SAEs reported in each group. One SAE, considered possibly related to CHC treatment, was a case of severe postprocedural hemorrhage that required reoperation. No patients needed dialysis. There were no observed rejections and no patient deaths.Conclusions. Pretreatment of kidneys with CHC before transplantation was considered safe and tolerable. Efficacy studies are now planned to investigate if CHC can reduce early ischemia-reperfusion injury in humans.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kirurgi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Surgery (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Urology and Nephrology (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Sedigh, Amir
-
Lundgren, Torbjö ...
-
Lindnér, Per, 19 ...
-
Nordström, Johan
-
Magnusson, Peetr ...
-
Jönsson, Janniz
-
visa fler...
-
Carlsson, Fredri ...
-
Ploeg, Rutger
-
Lorant, Tomas, 1 ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kirurgi
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Urologi och njur ...
- Artiklar i publikationen
-
Transplantation ...
- Av lärosätet
-
Uppsala universitet
-
Göteborgs universitet